1. 4CPS-162 Infliximab serum concentrations, antibody formation and clinical response in psoriatic patients. (2nd March 2018) Authors: Colls, M; Padullés, N; Padullés, A; Notario, J; Bas, J; Fernández, C Mariño; Colom, H Journal: European journal of hospital pharmacy Issue: Volume 25(2018)Supplement 1 Page Start: A117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Management of Tizanidine Withdrawal Syndrome: A Case Report. Issue 11 (13th February 2018) Authors: Suárez-Lledó, A; Padullés, A; Lozano, T; Cobo-Sacristán, S; Colls, M; Jódar, R Journal: Clinical medicine insights Issue: Issue 11(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PKP-008 Improving the quality of clinical decision making based on total phenytoin serum levels. (24th March 2015) Authors: Juvany, R; Colls, M; Dastis, M; Santulario, L; Leiva, E; Cobo, S; Dot, D; Jódar, R Journal: European journal of hospital pharmacy Issue: Volume 22(2015)Supplement 1 Page Start: A134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PKP-012 Body surface area, cigarrete smoking and infliximab response in patients with psoriasi. (14th February 2016) Authors: Colls, M; Padulles, N; Padullés, A; Notario, J; Bas, J; Sanmarti, N; Colom, H Journal: European journal of hospital pharmacy Issue: Volume 23(2016)Supplement 1 Page Start: A183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗